Published in Oncotarget on September 27, 2016
AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies. Oncotarget (2017) 0.75
Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol (1977) 6.30
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 5.90
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
Interleukin-2 augments natural killer cell activity. Nature (1981) 4.15
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80
Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J Exp Med (1984) 2.74
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Regulatory T cells and Foxp3. Immunol Rev (2011) 2.65
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol (2003) 2.42
Interleukin-2 induction of T-cell G1 progression and c-myb expression. Science (1986) 2.26
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother (2010) 2.18
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity (2015) 1.80
Early signals during CD8 T cell priming regulate the generation of central memory cells. J Immunol (2010) 1.49
Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells. J Immunol (2010) 1.48
CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010) 1.33
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res (2007) 1.32
Isolation of interleukin 2-induced immediate-early genes. Proc Natl Acad Sci U S A (1993) 1.23
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev (2015) 1.22
Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB (Oxford) (2012) 1.19
Spontaneous regression of malignant tumors: Importance of the immune system and other factors (Review). Oncol Lett (2010) 1.16
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol (2014) 1.11
High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer (2010) 1.07
DNA array analysis of interleukin-2-regulated immediate/early genes. Med Immunol (2002) 1.06
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist (2008) 1.05
Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol (2015) 1.05
Spontaneous regression of hepatocellular carcinoma: a case report and literature review. Hepatogastroenterology (2004) 1.01
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer (2003) 1.00
Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget (2015) 0.93
Sentinel Lymph Node Technique for Staging of Breast Cancer. Oncologist (1998) 0.82
Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer (2015) 0.81
S antigen specific effector T cell activation detected by cytokine flow cytometry. Br J Ophthalmol (2002) 0.79
Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol (2016) 0.79